Drug Search Results
More Filters [+]

S-777469

Alternative Names: s-777469, s777469
Latest Update: 2018-05-08
Latest Update Note: Clinical Trial Update

Product Description

S-777469 is an orally available CB2 agonist as an antipruritic agent. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22444677/)

Mechanisms of Action: CB2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shionogi
Company Location: OSAKA M0 541-0045
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for S-777469

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Dermatitis, Atopic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

0721D1424

P2

Completed

Dermatitis, Atopic

2009-05-01

39%

0710D1416

P2

Completed

Dermatitis, Atopic

2008-02-01

Recent News Events

Date

Type

Title